Pfenex

Pfenex is a biotechnology company based in San Diego, California, specializing in recombinant protein expression for various applications. The company's core technology, PfÄ«nex Expression Technology™, utilizes the BSL-1 microorganism Pseudomonas fluorescens and integrates an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unmatched speed and success in identifying protein production strains. Founded in 2009, PfÄ«nex focuses on applications such as therapeutic proteins, vaccines, research, reagents, and biosimilars. They received a $39.40MPost-IPO Equity investment on 29 May 2018. Although the last investment's details are not specified, Pfenex's innovative technology and its applications in the biotechnology, health care, and health and wellness industries make it an attractive prospect for potential investors.